Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.41 |
| ▸ | TUBB | P07437 | 2/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568504 | 0.91 | MAPT (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4568556 | 0.90 | MTNR1A (0.43) | TLR7TLR8MTNR1AMTNR1BTUBB4A | |
| SCHEMBL4568506 | 0.89 | MTNR1A (0.41) | TLR7TLR8MMP2MMP13MMP14 | |
| SCHEMBL4568512 | 0.85 | TUBB4A (0.44) | TLR7TLR8TUBB4ATUBBTUBA3C | |
| SCHEMBL4568582 | 0.85 | MTNR1A (0.39) | TLR7TLR8MMP2MMP13MMP14 | |
| SCHEMBL4568494 | 0.85 | MTNR1A (0.43) | TLR7TLR8MMP2MMP13MMP14 | |
| SCHEMBL4568497 | 0.85 | MTNR1A (0.45) | TLR7TLR8MTNR1AMTNR1BTUBB4A | |
| SCHEMBL4568505 | 0.83 | MTNR1A (0.43) | TLR7TLR8MMP2MMP13MMP14 | |
| SCHEMBL3705695 | 0.83 | MMP2 (0.44) | MMP2MMP13MMP14TUBB4ATUBB | |
| SCHEMBL4568502 | 0.83 | MTNR1A (0.43) | TLR7TLR8MTNR1AMTNR1BTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2474530-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | TLR7 1083/4885TLR8 1396/4885MMP2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.